{"classes":[{"categories":[{"measurements":[{"comment":"Upper confidence interval value could not be calculated as the fraction of participants experiencing events was too low.","groupId":"OG000","lowerLimit":"4.9","upperLimit":"NA","value":"9.0"},{"comment":"Median and confidence interval values could not be calculated as the fraction of participants experiencing events was too low.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Upper confidence interval value could not be calculated as the fraction of participants experiencing events was too low.","groupId":"OG002","lowerLimit":"10.60","upperLimit":"NA","value":"24.2"},{"groupId":"OG003","lowerLimit":"7.2","upperLimit":"14.8","value":"9.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"19"}],"units":"Participants"}],"description":"DOR is defined for participants with confirmed objective response (PR or better, which includes PR, VGPR, CR and sCR) as the time from the first documentation of objective response to the first documentation of objective progression or to death due to any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered IV melflufen at a dose of 30 mg on Day 1 of each 28-day cycle in combination with SQ bortezomib at a dose of 1.3mg/m\\^2 on Days 1, 4, 8, and 11 and dexamethasone PO at a dose of 20 mg (12 mg if the participants is ≥ 75 years of age) on Days 1, 4, 8, and 11 and 40 mg (20 mg if the participants is ≥ 75 years of age) on Day 15 and 22 of each 28-day cycle.","id":"OG000","title":"A (Melflufen+Bortezomib+Dex) 30 mg"},{"description":"Participants were administered IV melflufen at a dose of 40 mg on Day 1 of each 28-day cycle in combination with SQ bortezomib at a dose of 1.3mg/m\\^2 on Days 1, 4, 8, and 11 and dexamethasone PO at a dose of 20 mg (12 mg if the participants is ≥ 75 years of age) on Days 1, 4, 8, and 11 and 40 mg (20 mg if the participants is ≥ 75 years of age) on Day 15 and 22 of each 28-day cycle.","id":"OG001","title":"A (Melflufen+Bortezomib+Dex) 40 mg"},{"description":"Participants were administered IV melflufen at a dose of 30 mg on Day 1 of each 28-day cycle in combination with IV daratumumab at a dose of 16 mg/kg weekly for 8 doses, every other week for 8 doses and then once every 4 weeks. Participants were also administered dexamethasone orally (PO) at a dose of 40 mg weekly (20 mg weekly if the participants is ≥ 75 years of age).","id":"OG002","title":"B (Melflufen+Daratumumab+Dex) 30 mg"},{"description":"Participants were administered IV melflufen at a dose of 40 mg on Day 1 of each 28-day cycle in combination with IV daratumumab at a dose of 16 mg/kg weekly for 8 doses, every other week for 8 doses and then once every 4 weeks. Participants were also administered dexamethasone orally (PO) at a dose of 40 mg weekly (20 mg weekly if the participants is ≥ 75 years of age).","id":"OG003","title":"B (Melflufen+Daratumumab+Dex) 40 mg"}],"paramType":"MEDIAN","populationDescription":"Only participants included in the Safety Analysis Set who achieved a response of PR or better were included in this analysis.","reportingStatus":"POSTED","timeFrame":"Until disease progression, death or initiation of subsequent therapy (a maximum of 194.3 weeks)","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}